Boehringer Ingelheim Pharmaceuticals Inc. et al v. Mylan Pharmaceuticals Inc. et al > Summary
Court Case Number 1:24-cv-00082
Filing Date Aug 29, 2024
Court West Virginia Northern District Court
Status Unknown
JudgesThomas S. Kleeh
Defendant
Plaintiff Attorneys
10Boehringer Ingelheim Pharmaceuticals
Attorney Name: Christopher T. Ilardi
Kirkland & Ellis
Boehringer Ingelheim Pharmaceuticals
Attorney Name: David R. Pogue
Carey Douglas Kessler & Ruby PLLC
Boehringer Ingelheim Pharmaceuticals
Attorney Name: Eliana E. Applebaum
Kirkland & Ellis
Boehringer Ingelheim Pharmaceuticals
Attorney Name: James F. Hurst
Kirkland & Ellis
Boehringer Ingelheim Pharmaceuticals
Attorney Name: Jeanna M. Wacker
Kirkland & Ellis
Boehringer Ingelheim Pharmaceuticals
Attorney Name: Jordan Lee Damron
Carey Douglas Kessler & Ruby PLLC
Boehringer Ingelheim Pharmaceuticals
Attorney Name: Sam Kwon
Kirkland & Ellis
Boehringer Ingelheim Pharmaceuticals
Attorney Name: Steven R. Ruby
Carey Douglas Kessler & Ruby PLLC
Boehringer Ingelheim Pharmaceuticals
Attorney Name: Tasha Francis Gerasimow
Kirkland & Ellis
Defendant Attorneys
5Viatris Inc.
Attorney Name: Deepro R. Mukerjee
Katten Muchin Rosenman
Viatris Inc.
Attorney Name: Gordon H. Copland
Steptoe & Johnson PLLC
Viatris Inc.
Attorney Name: Joseph M. Janusz
Katten Muchin Rosenman
Viatris Inc.
Attorney Name: Lance A. Soderstrom
Katten Muchin Rosenman
Viatris Inc.
Attorney Name: William J. O'Brien
Steptoe & Johnson PLLC
Related Patents
| Doc No | Title | Issue date |
|---|---|---|
| 11911388 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | Feb 27, 2024 |
| 11033552 | DPP IV inhibitor formulations | Jun 15, 2021 |
